Figure 5 | Translational Psychiatry

Figure 5

From: Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin–proteasome systems

Figure 5

sGC-β1, PSMA2 and ubiquitination levels in human PBMCs from antidepressant responder and non-responder patients. (a) sGC-β1, PSMA2 and ubiquitination level differences between antidepressant non-responder (NR) and responder patients (R) at baseline (T0) and after 6 weeks treatment (T6), n=17. (b) Correlation of protein levels at T6 with clinical antidepressant treatment response, n=17. (c) Correlation of protein level changes (between T0 and T6) with clinical antidepressant treatment response, n=17. *P<0.05, **P<0.01 vs NR (two-tailed t-test). ##P<0.01, ###P<0.001, ####P<0.0001 vs T0 (two-tailed paired t-test). Data are expressed as the mean±s.e.m. The proteins were analysed using total lysate extract. Pearson correlation coefficients (r) with P-values are indicated in the correlation graphs. PBMC, peripheral blood mononuclear cell; PSMA2, proteasome subunit α type-2; sGC-β1, soluble guanylate cyclase-β1.

Back to article page